Editas Medicine's EDIT-401 Achieves ~90% Cholesterol Reduction in Primates; Human Trials Set for 2026
EDIT sits 91% above its 52-week low of $1.485.
Summary
Editas Medicine presented robust preclinical data for its lead gene-editing candidate, EDIT-401, demonstrating approximately 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates. This positive update follows earlier news regarding EDIT-401's progress, now providing specific efficacy numbers and a clear path forward. The company has received positive pre-IND feedback from the FDA and plans to submit a Clinical Trial Notification (CTN) by mid-2026 to initiate first-in-human trials in Australia later this year. These strong results for a key pipeline asset significantly advance its development. Early human proof-of-concept data for EDIT-401 is expected by the end of 2026.
At the time of this announcement, EDIT was trading at $2.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.2M. The 52-week trading range was $1.49 to $4.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.